Wade Wirta and Steven Schwager sit down to discuss the strengths and weaknesses of adaptive design as well as the logistical considerations to manage these complex trials.
Protocol amendments cost time and money, and it turns out that many of them are preventable.
The prospects of Big Data are tantalizing for the life sciences industry, but there’s still much left to do with small data.
Life science companies are continuously looking for ways to advance clinical research while simultaneously improving the understanding of drugs they are developing.
Dave Gemzik, Medidata’s Principal for Strategic Consulting Services, will speak at the DIA Annual Meeting in Washington, DC about creating high quality clinical trial protocols through a data-driven approach.